文献速递消化道肿瘤放疗

食管癌根治性放疗剂量提升模式:2006-2016年

Patterns of Dose Escalation Among Patients With Esophageal Cancer Undergoing Definitive Radiation Therapy: 2006-2016.
PubMed 文献 · Adv Radiat Oncol · 2020-10-09

基于美国国家癌症数据库分析2006-2016年非转移性T2+食管癌接受化疗和放疗(41.4-74 Gy)且未手术的患者,共14,517例。最常见剂量为50.4 Gy(47.9%),>50.4 Gy剂量提升占30.6%,且逐年下降(2006年42.2%至2016年23.5%)。鳞癌和颈段食管癌患者剂量提升的调整比值比更高。

要点

  • 2006-2016年间食管癌根治性放化疗剂量提升比例从42.2%降至23.5%。
  • 鳞癌较腺癌更易接受>50.4 Gy剂量提升(AOR 1.46,P<.001)。
  • 颈段食管癌较非颈段更易剂量提升(AOR 2.51,P<.001)。

核心结论

  • 食管癌根治性放化疗中剂量提升随时间下降,尤其在腺癌和非颈段原发部位。

研究设计与样本

  • 使用美国国家癌症数据库识别2006-2016年非转移性T2+食管癌接受化疗和放疗(41.4-74 Gy)且未手术的患者,共14,517例。

主要发现

  • 最常见剂量为50.4 Gy,用于6955例(47.9%)患者。
  • >50.4 Gy剂量提升见于4440例(30.6%)患者,从2006年42.2%下降至2016年23.5%。
  • 鳞癌较腺癌剂量提升比例更高(39.3% vs 23.8%;AOR 1.46;P<.001)。
  • 颈段食管癌较其他原发部位剂量提升比例更高(54.9% vs 27.4%;AOR 2.51;P<.001)。
  • 诊断年份较晚对腺癌的影响大于鳞癌(pint=0.001,AOR 0.54,P<.001 vs AOR 0.71,P<.001),且对非颈段食管癌显著(pint<0.001,AOR 0.56,P<.001 vs AOR 0.95,P=.616)。

关键数值与推荐

  • 纳入放疗剂量范围为41.4-74 Gy。
  • 剂量提升定义为>50.4 Gy。

临床怎么用

  • 鉴于ARTDECO试验结果,本研究可作基准以监测未来实践模式变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although single-institution series suggest potential benefit to dose escalation in definitive radiation therapy for esophageal cancer, randomized trials including intergroup-0123 and the recently presented A Randomized Trial of Dose Escalation in definitive Chemoradiotherapy for patients with Oesophageal cancer (ARTDECO) trial showed no improvement in outcomes with higher radiation therapy dose. As such, there may be significant variation in radiation dose for definitive treatment of esophageal cancer. METHODS AND MATERIALS: The National Cancer Database was used to identify patients who received a diagnosis of nonmetastatic T2+ esophageal cancer between 2006 and 2016 who did not receive definitive surgery and were treated with chemotherapy and radiation therapy doses between 41.4 and 74 Gy. Multivariable logistic regression defined adjusted odds ratios (AORs) of receipt of >50.4 Gy, including year of diagnosis (2006-2013 vs 2014-2016) ∗ histology (squamous cell carcinoma [SCC] vs adenocarcinoma) and year of diagnosis (2006-2013 vs 2014-2016) ∗ disease site (cervical esophagus vs noncervical esophagus) interaction terms, to assess whether the effect of diagnosis year on dose varied by histology and disease site, respectively. RESULTS: Among 14,517 patients, the most common dose was 50.4 Gy, used for 6955 (47.9%) patients. Dose escalation above 50.4 Gy was observed in 4440 (30.6%) patients and declined by year, from 42.2% in 2006 to 23.5% in 2016. Patients with SCC versus adenocarcinoma had higher odds of dose escalation (39.3% vs 23.8%; AOR 1.46; P < .001), as did those with cervical esophageal primaries versus other primary sites (54.9% vs 27.4%; AOR 2.51; P < .001). The effect of later diagnosis year was greater for adenocarcinoma than for SCC (pint = 0.001, AOR 0.54, P < .001 vs AOR 0.71, P < .001) and significant for noncervical esophagus but not cervical esophagus (pint <0.001, AOR 0.56, P < .001 vs AOR 0.95, P = .616). CONCLUSIONS: Dose escalation in definitive chemoradiotherapy for esophageal cancer declined over time, particularly for adenocarcinoma histology and noncervical primary site. Given the recent results of ARTDECO, our findings can serve as a benchmark from which to measure future shifts in practice patterns.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang-Velten ER, Eraj SA, Hein DM, et al. Patterns of Dose Escalation Among Patients With Esophageal Cancer Undergoing Definitive Radiation Therapy: 2006-2016. Adv Radiat Oncol. 2020. PMID: 33732955. doi:10.1016/j.adro.2020.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。